Evaluation of the anti-radiation effectiveness of a drug encapsulated in a liposome

Prevention and treatment of acute radiation sickness in animals is one of the leading areas of development and improvement of anti-radiation drugs. The human and animal body does not contain specific receptors for the touch of ionizing radiation, but in turn, gamma quanta respond by ionizing the molecules of biological structures and aqueous media. As a result of the formation of free radicals, secondary damage to biological structures occurs. The main danger to the body is the formation of free radicals that damage the cells and structures of the body. Therefore, the body’s main defense during radiation sickness is to neutralize free radicals and restore damaged structures-target cells. For this purpose, radioprotective drugs with different mechanisms of action have been developed and are being developed. The most effective use of such products is in liposomal form. Taking into account the urgency of the problem, employees of the Federal State Budgetary Institution "FCTRB-VNTVI" have developed a technology for obtaining a liposomal form of a conjugated anti-radiation agent, which will be a promising means of delivering biologically active compounds to the localization of radiolysis products in organs and tissues exposed to ionizing radiation.